The potential of the [18F]-FB-anti-HER2 nanobody to be translated into the clinic is supported by how its simultaneous administration with Trastuzumab does not compromise its accuracy in capturing tumor cell HER2 expression, as the two antibodies target non-overlapping epitopes [56]. This evidence concerns the gene ERBB2 and neoplasm.